Tenaya Therapeutics, Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 45/100
What the filing says
Tenaya Therapeutics filed an 8-K on July 2, 2026 reporting termination of a material definitive agreement effective June 29, 2026 (Item 1.02). The filing document itself does not disclose the counterparty, dollar amounts, financial terms, or nature of the terminated agreement—only that a material agreement was terminated.
Why this rating
Material agreement termination is ordinarily significant, but disclosure vacuum prevents assessment. Relative to $63.1M market cap, unknown dollar exposure creates uncertainty. Likely moderate-to-significant if agreement was material to operations or financing.
Extracted items
- 1.02 agreement termination
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.